$2.71
1.12% day before yesterday
Nasdaq, Nov 28, 09:46 pm CET
ISIN
US12529R1077
Symbol
CCCC

C4 Therapeutics Inc Stock price

$2.71
+0.13 5.04% 1M
+1.45 115.08% 6M
-0.89 24.72% YTD
-1.84 40.44% 1Y
-5.24 65.91% 3Y
-31.49 92.08% 5Y
-16.29 85.74% 10Y
-16.29 85.74% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
+0.03 1.12%
ISIN
US12529R1077
Symbol
CCCC
Industry

Key metrics

Basic
Market capitalization
$262.6m
Enterprise Value
$70.8m
Net debt
positive
Cash
$191.9m
Shares outstanding
74.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.7 | 9.2
EV/Sales
2.4 | 2.5
EV/FCF
negative
P/B
1.7
Financial Health
Equity Ratio
61.8%
Return on Equity
-48.8%
ROCE
-51.9%
ROIC
-223.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$30.1m | $28.6m
EBITDA
$-117.0m | $-113.2m
EBIT
$-119.1m | $-121.3m
Net Income
$-119.1m | $-117.6m
Free Cash Flow
$-95.1m
Growth (TTM | estimate)
Revenue
-10.6% | -19.5%
EBITDA
-1.7% | 1.9%
EBIT
-1.8% | -3.5%
Net Income
-12.9% | -11.7%
Free Cash Flow
-32.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-388.7% | -395.3%
EBIT
-395.4%
Net
-395.5% | -410.5%
Free Cash Flow
-315.8%
More
EPS
$-1.6
FCF per Share
$-1.3
Short interest
5.3%
Employees
110
Rev per Employee
$320.0k
Show more

Is C4 Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

C4 Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a C4 Therapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a C4 Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from C4 Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
30 30
11% 11%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 37 37
11% 11%
124%
- Research and Development Expense 112 112
3% 3%
371%
-117 -117
2% 2%
-389%
- Depreciation and Amortization 2.01 2.01
14% 14%
7%
EBIT (Operating Income) EBIT -119 -119
2% 2%
-395%
Net Profit -119 -119
13% 13%
-395%

In millions USD.

Don't miss a Thing! We will send you all news about C4 Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

C4 Therapeutics Inc Stock News

Positive
Seeking Alpha
3 days ago
C4 Therapeutics reported a Q3 GAAP EPS loss of –$0.44, missing estimates, but revenue of $11.23M beat expectations by $4.95M. CCCC's lead asset, cemsidomide, showed promising Phase 1 results in multiple myeloma and is advancing to pivotal Phase 2 and combination trials in 2026. Despite a net loss and heavy R&D spending, the company boasts a strong cash position and trades at a discount to secto...
Neutral
GlobeNewsWire
4 days ago
WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference taking place from December 2 - 4, 2025 in Coral Gables, Florida.
Positive
Seeking Alpha
17 days ago
Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance. SiTime Corp. was also a top contributor. The company provides silicon timing chips for a wide range of electronics. The greatest detractor from Fund performance for the quarter was Monday.com Ltd.
More C4 Therapeutics Inc News

Company Profile

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Hirsch
Employees 110
Founded 2015
Website c4therapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today